Disclosed herein are adiponectin receptor agonists and methods of using the same for the treatment of inflammation or bone loss in a subject.

Thrombomodulin functional domains for use in promoting osteoblast functions and bone healing. Methods for stimulating bone regeneration, bone augmentation, treating a bone loss, a bone disorder and/or treating a bone-related disorder are disclosed. The method comprises administering, to a subject in need thereof a therapeutically effective amount of (I); a biologically, active recombinant polypeptide comprising, an amino acid sequence that is at least 80% identical to domains 2 and 3 of human thrombomodulin (TMD23); (II): an isolated polypeptide comprising recombinant TMD23 (rTMD23) or a biologically active recombinant variant thereof; or recombinant TMD23 (rTMD23) or a biologically active recombinant variant thereof, wherein the polypeptide is free of or lacking amino acid residues from domains 4 and 5 of the human thrombomodulin, and further wherein the biologically active variant thereof comprises an amino acid sequence that is at least 80% identical to the TMD23.

Thrombomodulin functional domains for use in promoting osteoblast functions and bone healing. Methods for stimulating bone regeneration, bone augmentation, treating a bone loss, a bone disorder and/or treating a bone-related disorder are disclosed. The method comprises administering, to a subject in need thereof a therapeutically effective amount of (I); a biologically, active recombinant polypeptide comprising, an amino acid sequence that is at least 80% identical to domains 2 and 3 of human thrombomodulin (TMD23); (II): an isolated polypeptide comprising recombinant TMD23 (rTMD23) or a biologically active recombinant variant thereof; or recombinant TMD23 (rTMD23) or a biologically active recombinant variant thereof, wherein the polypeptide is free of or lacking amino acid residues from domains 4 and 5 of the human thrombomodulin, and further wherein the biologically active variant thereof comprises an amino acid sequence that is at least 80% identical to the TMD23.

The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.

Provided herein are methods for the production of native and reconstituted hyaluronan (HA) complexes containing pentraxin-3 (PTX3) and heavy chain 1 (HC1) of inter alpha inhibitor (IαI). Compositions containing the complexes and therapeutic methods using the complexes are provided. Combinations and kits for use in practicing the methods also are provided.

The present disclosure relates to compounds that are Syk inhibitors or pharmaceutically acceptable salts or co-crystals thereof, and pharmaceutical compositions thereof, and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, a Syk inhibitor is a crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo-[1,2-a]pyrazin-8-amine of formula 2: ##STR00001##

The present invention relates to a combination of a CNP agonist and at least one further biologically active moiety or drug for use in a method for the treatment or prevention of disorders that benefit from stimulating growth, pharmaceutical compositions comprising at least one CNP agonist, preferably controlled-release CNP agonist, wherein the pharmaceutical composition comprises at least one further biologically active moiety or drug, to using these pharmaceutical compositions as a medicament, to their use in the treatment of disorders that benefit from stimulating growth and to methods of preventing or treating a patient having a disorder that benefits from stimulating growth.

The present invention relates to a combination of a CNP agonist and at least one further biologically active moiety or drug for use in a method for the treatment or prevention of disorders that benefit from stimulating growth, pharmaceutical compositions comprising at least one CNP agonist, preferably controlled-release CNP agonist, wherein the pharmaceutical composition comprises at least one further biologically active moiety or drug, to using these pharmaceutical compositions as a medicament, to their use in the treatment of disorders that benefit from stimulating growth and to methods of preventing or treating a patient having a disorder that benefits from stimulating growth.

Provided are compositions and methods for preventing, mitigating, decreasing, inhibiting and/or reversing bone loss and/or increasing and/or promoting bone regeneration and remodeling and/or preventing, mitigating, decreasing, inhibiting and/or reversing periodontitis and/or periodontal disease in a subject by administering to the subject an effective amount of an inhibitor of soluble epoxide hydrolase (sEH).

Provided are compositions and methods for preventing, mitigating, decreasing, inhibiting and/or reversing bone loss and/or increasing and/or promoting bone regeneration and remodeling and/or preventing, mitigating, decreasing, inhibiting and/or reversing periodontitis and/or periodontal disease in a subject by administering to the subject an effective amount of an inhibitor of soluble epoxide hydrolase (sEH).